Royal Bank of Canada’s Gyre Therapeutics GYRE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $39K | Sell |
5,605
-7,160
| -56% | -$55.6K | ﹤0.01% | 5603 |
|
|
2025
Q4 | $91K | Buy |
12,765
+370
| +3% | +$2.86K | ﹤0.01% | 5248 |
|
|
2025
Q3 | $92K | Buy |
12,395
+6,133
| +98% | +$46.6K | ﹤0.01% | 5551 |
|
|
2025
Q2 | $45K | Buy |
6,262
+5,870
| +1,497% | +$51.2K | ﹤0.01% | 5969 |
|
|
2025
Q1 | $3K | Sell |
392
-418
| -52% | -$4.58K | ﹤0.01% | 6485 |
|
|
2024
Q4 | $10K | Sell |
810
-154
| -16% | -$1.97K | ﹤0.01% | 6344 |
|
|
2024
Q3 | $12K | Sell |
964
-88
| -8% | -$1.14K | ﹤0.01% | 6281 |
|
|
2024
Q2 | $13K | Buy |
+1,052
| New | +$14.4K | ﹤0.01% | 6241 |
|
|
2023
Q4 | – | Sell |
-17
| Closed | – | – | 7308 |
|
|
2023
Q3 | $0 | Buy |
+17
| New | +$114 | ﹤0.01% | 7278 |
|
|
2023
Q2 | – | Sell |
-1
| Closed | – | – | 7404 |
|
|
2023
Q1 | $0 | Hold |
1
| – | – | ﹤0.01% | 7230 |
|
|
2022
Q4 | $0 | Buy |
+1
| New | +$4 | ﹤0.01% | 7418 |
|
|
2021
Q3 | – | Sell |
-290
| Closed | -$9K | – | 7721 |
|
|
2021
Q2 | $9K | Sell |
290
-97
| -25% | -$3.33K | ﹤0.01% | 6910 |
|
|
2021
Q1 | $15K | Buy |
387
+129
| +50% | +$5.9K | ﹤0.01% | 6597 |
|
|
2020
Q4 | $12K | Buy |
258
+256
| +12,800% | +$11.1K | ﹤0.01% | 6296 |
|
|
2020
Q3 | $0 | Buy |
+2
| New | +$78 | ﹤0.01% | 6740 |
|
|
2020
Q1 | – | Hold |
0
| – | – | – | 6802 |
|
|
2019
Q4 | – | Hold |
0
| – | – | – | 6929 |
|
|
2018
Q4 | – | Sell |
-31
| Closed | -$2K | – | 6895 |
|
|
2018
Q3 | $2K | Buy |
+31
| New | +$2.46K | ﹤0.01% | 6508 |
|
|
2018
Q2 | – | Hold |
0
| – | – | – | 6621 |
|
|
2017
Q2 | – | Sell |
-1
| Closed | – | – | 6637 |
|
|
2017
Q1 | $0 | Sell |
1
-1
| -50% | -$58 | ﹤0.01% | 6686 |
|
|
2016
Q4 | $0 | Hold |
2
| – | – | ﹤0.01% | 6688 |
|
|
2016
Q3 | $0 | Hold |
2
| – | – | ﹤0.01% | 6461 |
|
|
2016
Q2 | $0 | Buy |
+2
| New | +$341 | ﹤0.01% | 6426 |
|
|
2015
Q4 | – | Sell |
-68
| Closed | -$36K | – | 6714 |
|
|
2015
Q3 | $36K | Buy |
+68
| New | +$104K | ﹤0.01% | 5305 |
|
|
2015
Q2 | – | Hold |
0
| – | – | – | 6446 |
|
Other funds holding GYRE
VCM
SS
VFT
VPM
Royal Bank of Canada's GYRE Position: Q1 2026 in Review
Royal Bank of Canada reduced its Gyre Therapeutics (GYRE) stake by 56% in Q1 2026, selling an estimated $55.6K and leaving 5,605 shares worth $39K. The position accounts for ﹤0.01% of the portfolio, ranked #5603.
Royal Bank of Canada first reported a position in GYRE in Q3 2015 and has held it in 21 quarters since. The position peaked at $92K in Q3 2025. 56 funds tracked by Wall St. Rank hold GYRE as of Q1 2026.
- Royal Bank of Canada held 5,605 shares of Gyre Therapeutics worth $39K as of Q1 2026.
- Royal Bank of Canada sold 7,160 Gyre Therapeutics shares in Q1 2026, an estimated $55.6K.
- Gyre Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #5603 holding.
- Royal Bank of Canada first reported a position in Gyre Therapeutics in Q3 2015 and has held it in 21 quarters since.
- Royal Bank of Canada's Gyre Therapeutics position peaked at $92K in Q3 2025.
- 56 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q1 2026.
Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.